Evidence map›Paper›PMID 38573891›Full record

ArticlePloS one2024

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.

Tarun Mehra, Judith E Lupatsch, Thibaud Kössler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, Matthias E Schwenkglenks

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Tarun MehraDepartment of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland.ORCID 0009-0005-8429-5110
Judith E LupatschDepartment of Public Health, Institute of Pharmaceutical Medicine (ECPM) and Health Economics Facility, University of Basel, Basel, Switzerland.
Thibaud KösslerService d'oncologie, Hôpitaux Universitaires Genève, Genève, Switzerland.
Konstantin DedesBreast Cancer Center Zürichsee, Zurich, Switzerland.
Alexander Reinhard SiebenhünerOnkozentrum Hirslanden Zurich AG and University of Zurich, Zurich, Switzerland.
Roger von MoosDepartment of Medical Oncology and Hematology, Cantonal Hospital of Graubünden, Chur, Switzerland.
Andreas WickiDepartment of Medical Oncology and Hematology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.
Matthias E SchwenkglenksDepartment of Public Health and Head of Research, Health Economics Facility, Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland.ORCID 0000-0001-7217-1173
University of Basel · CHUniversity of Zurich · CHBreast Center · CHHôpital Beau-Séjour · CHKantonsspital Graubünden · CHUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the cost-effectiveness and budget impact of olaparib as a maintenance therapy in platinum-responsive, metastatic pancreatic cancer patients harboring a germline BRCA1/2 mutation, using the Swiss context as a model.

methodsBased on data from the POLO trial, published literature and local cost data, we developed a partitioned survival model of olaparib maintenance including full costs for BRCA1/2 germline testing compared to FOLFIRI maintenance chemotherapy and watch-and-wait. We calculated the incremental cost-effectiveness ratio (ICER) for the base case and several scenario analyses and estimated 5-year budget impact.

resultsComparing olaparib with watch-and wait and maintenance chemotherapy resulted in incremental cost-effectiveness ratios of CHF 2,711,716 and CHF 2,217,083 per QALY gained, respectively. The 5-year costs for the olaparib strategy in Switzerland would be CHF 22.4 million, of which CHF 11.4 million would be accounted for by germline BRCA1/2 screening of the potentially eligible population. This would amount to a budget impact of CHF 15.4 million (USD 16.9 million) versus watch-and-wait.

conclusionsOlaparib is not a cost-effective maintenance treatment option. Companion diagnostics are an equally important cost driver as the drug itself.

Indexed as

Ovarian NeoplasmsPancreatic NeoplasmsPiperazinesBRCA1 ProteinBRCA2 ProteinCost-Benefit AnalysisFemaleGerm CellsHumansPhthalazinesPlatinumBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanolaparibPhthalazinesPiperazinesPlatinum

Identifiers

PMID38573891
PMCPMC10994352
OpenAlexW4393929870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.